Similar to other malignancies, glioblastoma (GBM) achieves immune escape through multiple pathways, comprising elevated expression of immune checkpoint ligands (e.g., PD-L1, Fas-L), reduced major histocompatibility complex (MHC) presentation and diminished co-stimulatory molecule expression (132–134). The gene discussed is HLA-C; the disease is glioblastoma.